0.0001USDMkt Cap: —P/E: —3d ago
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has comple…
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap—
Enterprise Value-11.21M $
Revenue (TTM)5.64M $
Gross Profit5.64M $
Net Income (TTM)-69.97M $
Revenue/Share0.3660 USD
Last Price0.0001 USD
Fiscal Year EndDec 2023
MR QuarterSep 2024
Employees76
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA0.18
EV/Revenue-1.99
P/S—
P/B0.00
EPS (TTM)-0.66
EPS (Forward)—
52W Range
—
52W High0.0001 USD
52W Low0.0001 USD
Profitability
Gross Margin100.00%
Oper. Margin-8709.15%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-149.49%
ROA-49.42%
Growth
Revenue Growth-91.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-76.90M $
CapEx (TTM)—
FCF Margin-805.14%
FCF Yield—
Net Debt-11.21M $
Net Debt/EBITDA0.18
Balance Sheet
Debt/Equity74.96
Current Ratio1.93
Quick Ratio1.71
Book Value/Sh1.214 USD
Cash/Share1.470 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split0.1:1
Split DateMar 11, 2024
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float15.48M
Insiders0.00%
Institutions0.00%
Technical
SMA 505.510 (-100.0%)
SMA 2005.863 (-100.0%)
Beta0.30
S&P 52W Chg18.16%
Avg Vol (30d)565
Avg Vol (10d)1.15K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—